Oxybutynin Chloride ER (Oxybutynin Chloride) Patent Expiration, LOE Window & CMS Spending

Oxybutynin Chloride ER (Oxybutynin Chloride) by Ajanta L: Off-Patent Genericized (AB Competition), 20 AB generics, $85.5M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAjanta L
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors20
2024 CMS Total Public Spend$85.5M
2024 Medicare Part D Spend$76.3M
2024 Medicaid Spend$9.2M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel